Essa Y. Baitei

King Faisal Specialist Hospital & Research Centre — Saudi Arabia

Medicine · Health Sciences

21h-index1.1kcitations49works4.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Thyroid Cancer Diagnosis and Treatment(14), Cancer-related Molecular Pathways(12), Occupational and environmental lung diseases(12), Vitamin D Research Studies(5), Thyroid Disorders and Treatments(5)

Publications49 total

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial
Nature Communications·2025· 3 citedOpen Access
12P Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma
Immuno-Oncology Technology·2024Open Access
117 (PB105): Peroxiredoxin 3 (PRX3) – a new target for the treatment of aggressive cancers.
European Journal of Cancer·2024
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma
Nature Communications·2024· 22 citedOpen Access
61 The first-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 modulates the mesenchymal and immune phenotype in mesothelioma
Lung Cancer·2024· 1 cited
Abstract 4716: First-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 triggers mesenchymal-to-epithelial transition in mesothelioma
Cancer Research·2024
Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma.
Journal of Clinical Oncology·2023· 3 cited
A gut microbiota rheostat to forecast response to PDL1-VEGF blockade in mesothelioma.
Journal of Clinical Oncology·2023· 1 cited
Supplementary Table 2 from <i>Cyp24a1</i> Attenuation Limits Progression of <i>Braf<sup>V600E</sup></i>-Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAF<sup>V600E</sup> Inhibitor PLX4720
2023Open Access
Supplementary Table 2 from <i>Cyp24a1</i> Attenuation Limits Progression of <i>Braf<sup>V600E</sup></i>-Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAF<sup>V600E</sup> Inhibitor PLX4720
2023Open Access
Supplementary Table 1 from <i>Cyp24a1</i> Attenuation Limits Progression of <i>Braf<sup>V600E</sup></i>-Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAF<sup>V600E</sup> Inhibitor PLX4720
2023Open Access
Supplementary Table 3 from <i>Cyp24a1</i> Attenuation Limits Progression of <i>Braf<sup>V600E</sup></i>-Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAF<sup>V600E</sup> Inhibitor PLX4720
2023Open Access
Supplementary Table 3 from <i>Cyp24a1</i> Attenuation Limits Progression of <i>Braf<sup>V600E</sup></i>-Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAF<sup>V600E</sup> Inhibitor PLX4720
2023Open Access
Supplementary Table 1 from <i>Cyp24a1</i> Attenuation Limits Progression of <i>Braf<sup>V600E</sup></i>-Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAF<sup>V600E</sup> Inhibitor PLX4720
2023Open Access
Data from <i>Cyp24a1</i> Attenuation Limits Progression of <i>Braf<sup>V600E</sup></i>-Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAF<sup>V600E</sup> Inhibitor PLX4720
2023Open Access
Data from <i>Cyp24a1</i> Attenuation Limits Progression of <i>Braf<sup>V600E</sup></i>-Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAF<sup>V600E</sup> Inhibitor PLX4720
2023Open Access
28P Epithelial mesenchymal transition confers resistance to dual PDL1-VEGF inhibition in relapsed mesothelioma
Immuno-Oncology Technology·2022Open Access
Abstract 6086: Clonal biallelic inactivation of NF2 is an evolutionary bottleneck that exposes a vulnerability to CDK7 inhibition in mesothelioma
Cancer Research·2022
Abstract 1613: Systematic screening for genomic vulnerabilities as drug targets for mesothelioma
Cancer Research·2022
Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
Nature Communications·2021· 9 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Minjing Zou(35), Yufei Shi(34), Brian F. Meyer(23), Ali S. Alzahrani(21), Futwan Al‐Mohanna(21), Ranjit S. Parhar(19), Catrin Pritchard(16), Roua A. Al‐Rijjal(14), Huda A. BinEssa(13), Charlotte Poile(12), Aleksandra Bzura(11), Joanna Działo(11), Shioko Kimura(11), Dean A. Fennell(10), Abdullah M. Assiri(10), René St‐Arnaud(9), Apostolos Nakas(8), Min Zhang(7), James Harber(7), Peter Wells-Jordan(7)